

# David L Kendler

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1282896/david-l-kendler-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117  
papers

10,935  
citations

48  
h-index

104  
g-index

120  
ext. papers

12,572  
ext. citations

6.6  
avg, IF

5.5  
L-index

#	Paper	IF	Citations
117	Romosozumab and antiresorptive treatment: the importance of treatment sequence.. <i>Osteoporosis International</i> , <b>2022</b> , 1	5.3	2
116	A retrospective observational study of osteoporosis management after a fragility fracture in primary care.. <i>Archives of Osteoporosis</i> , <b>2022</b> , 17, 75	2.9	1
115	Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. <i>Advances in Therapy</i> , <b>2021</b> , 39, 58	4.1	2
114	Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. <i>Journal of Bone Oncology</i> , <b>2021</b> , 28, 100361	4.5	4
113	The association between trunk muscle endurance, balance and falls self-efficacy in women with osteoporotic vertebral fractures: an exploratory analysis from a pilot randomized controlled trial. <i>Disability and Rehabilitation</i> , <b>2021</b> , 43, 2268-2274	2.4	0
112	A scorecard for osteoporosis in Canada and seven Canadian provinces. <i>Osteoporosis International</i> , <b>2021</b> , 32, 123-132	5.3	3
111	Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 397-409	5.6	10
110	Efficacy of teriparatide compared with risedronate on FRAX-defined major osteoporotic fractures: results of the VERO clinical trial. <i>Osteoporosis International</i> , <b>2020</b> , 31, 1935-1942	5.3	7
109	Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial. <i>Calcified Tissue International</i> , <b>2020</b> , 106, 646-654	3.9	3
108	Persistence and adherence to parenteral osteoporosis therapies: a systematic review. <i>Osteoporosis International</i> , <b>2020</b> , 31, 2093-2102	5.3	17
107	Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. <i>Bone</i> , <b>2020</b> , 134, 115287	4.7	6
106	Bone Mineral Density After Transitioning From Denosumab to Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	33
105	Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	
104	The Effects of Home Exercise in Older Women With Vertebral Fractures: A Pilot Randomized Controlled Trial. <i>Physical Therapy</i> , <b>2020</b> , 100, 662-676	3.3	9
103	Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. <i>Bone</i> , <b>2020</b> , 130, 115113	4.7	4
102	Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , <b>2019</b> , 22, 489-500	3.5	9
101	Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. <i>Archives of Osteoporosis</i> , <b>2019</b> , 14, 10	2.9	4

100	Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. <i>American Journal of Medicine</i> , <b>2019</b> , 132, e771-e777	2.4	9
99	Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 3450-3461	5.6	11
98	Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. <i>Osteoporosis International</i> , <b>2019</b> , 30, 2437-2448	5.3	44
97	Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. <i>Bone</i> , <b>2019</b> , 120, 1-8	4.7	54
96	Score Distributions of the Balance Outcome Measure for Elder Rehabilitation (BOOMER) in Community-Dwelling Older Adults With Vertebral Fracture. <i>Journal of Geriatric Physical Therapy</i> , <b>2019</b> , 42, E87-E93	3.2	1
95	Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 783-794	6.3	59
94	Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 298-306	6.3	48
93	Diagnosis and management of bone fragility in diabetes: an emerging challenge. <i>Osteoporosis International</i> , <b>2018</b> , 29, 2585-2596	5.3	141
92	Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2498-2509	5.6	51
91	Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 230-240	4.0	244
90	Management of Male Osteoporosis: an Update. <i>Current Treatment Options in Rheumatology</i> , <b>2018</b> , 4, 355-366	1.3	
89	Teriparatide vs risedronate for osteoporosis - AuthorsTreply. <i>Lancet, The</i> , <b>2018</b> , 391, 1896	4.0	1
88	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2017</b> , 5, 513-523	18.1	419
87	Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 862.e1-862.e7	2.4	14
86	Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. <i>Journal of Clinical Densitometry</i> , <b>2017</b> , 20, 8-24	3.5	125
85	Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 207-214	3.1	17
84	Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1585-1594	4.0	205
83	High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 221-229	3.1	8

82	Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. <i>Menopause</i> , <b>2016</b> , 23, 1083-91	2.5	14
81	Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 1353-63	5.6	42
80	Audit of Atypical Femoral Fractures and a Description of Some of Their Features. <i>Canadian Association of Radiologists Journal</i> , <b>2016</b> , 67, 69-75	3.9	5
79	Vertebral Fractures: Clinical Importance and Management. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 221.e1-10	139	
78	Implementation of a Physician-Prescribed Exercise Program As Standard of Care in Allogeneic Stem Cell Transplant (SCT) Patients (pts) in British Columbia: A Pilot Study. <i>Blood</i> , <b>2016</b> , 128, 3603-3603	2.2	1
77	A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1429-39	6.3	40
76	Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1827-1834	6.3	52
75	Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology. <i>Bone</i> , <b>2015</b> , 81, 122-130	4.7	37
74	A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1335-42	5.6	80
73	Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 3-23	6.3	680
72	Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. <i>Journal of Bone and Mineral Research</i> , <b>2014</b> , 29, 2051-6	6.3	47
71	Build better bones with exercise: protocol for a feasibility study of a multicenter randomized controlled trial of 12 months of home exercise in women with a vertebral fracture. <i>Physical Therapy</i> , <b>2014</b> , 94, 1337-52	3.3	15
70	Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia. <i>Calcified Tissue International</i> , <b>2014</b> , 94, 665-8	3.9	20
69	Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2014</b> , 17, 490-5	3.5	14
68	Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2014</b> , 96, e90	5.6	29
67	Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. <i>Journal of Bone and Mineral Research</i> , <b>2014</b> , 29, 158-65	6.3	85
66	Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. <i>Menopause</i> , <b>2014</b> , 21, 25-32	2.5	27
65	Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. <i>Canadian Family Physician</i> , <b>2014</b> , 60, 324-33	0.9	82

64	High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. <i>Current Osteoporosis Reports</i> , <b>2013</b> , 11, 136-46	5.4	148
63	Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 250-6	3.5	24
62	The Official Positions of the International Society for Clinical Densitometry: Indications of Use and Reporting of DXA for Body Composition. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 496-507	3.5	68
61	Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 13-20	2.4	326
60	Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium. <i>Journal of Pediatric Orthopaedics</i> , <b>2013</b> , 33, 269-75	2.4	42
59	The generalized bone phenotype in children with neurofibromatosis 1: a sibling matched case-control study. <i>American Journal of Medical Genetics, Part A</i> , <b>2013</b> , 161A, 1654-61	2.5	17
58	Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 687-93	6.3	139
57	Femoral fractures in osteoporotic patients on bisphosphonates. A case report. <i>Journal of Clinical Densitometry</i> , <b>2012</b> , 15, 380-4	3.5	4
56	Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, e89-96	4.5	78
55	A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 3161-9	5.6	138
54	Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 2799-808	5.6	73
53	Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. <i>Journal of Clinical Densitometry</i> , <b>2011</b> , 14, 226-36	3.5	34
52	MIA is a potential biomarker for tumour load in neurofibromatosis type 1. <i>BMC Medicine</i> , <b>2011</b> , 9, 82	11.4	13
51	Effect of alendronate and vitamin D on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 1836-44	6.3	16
50	Preventing fractures in postmenopausal women: how to assess risk. <i>Cmaj</i> , <b>2011</b> , 183, 2129-31	3.5	
49	Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 972-80	5.6	355
48	Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation. <i>Orthopedic Research and Reviews</i> , <b>2010</b> , Volume 2, 49-69	2.1	
47	Lasofoxifene in postmenopausal women with osteoporosis. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 686-96	59.2	295

46	International Society for Clinical Densitometry official positions: Asia-Pacific Region consensus. <i>Journal of Clinical Densitometry</i> , <b>2010</b> , 13, 346-51	3.5	18
45	Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 72-81	6.3	318
44	Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 2239-50	6.3	125
43	Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 2256-65	6.3	173
42	Bisphosphonate associated osteonecrosis of the jaw. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 478-90	4.1	131
41	Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. <i>American Journal of Medical Genetics, Part A</i> , <b>2009</b> , 149A, 2327-38	2.5	97
40	Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 1544-51	6.3	94
39	Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. <i>American Journal of Medicine</i> , <b>2009</b> , 122, 992-7	2.4	17
38	Implementation of osteoporosis screening guidelines in prostate cancer patients on androgen ablation. <i>Journal of Clinical Densitometry</i> , <b>2009</b> , 12, 287-91	3.5	7
37	Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 75-91	3.5	344
36	Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 2149-57	5.6	290
35	Use of lowest single lumbar spine vertebra bone mineral density T-score and other T-score approaches for diagnosing osteoporosis and relationships with vertebral fracture status. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 525-31	3.5	5
34	Dual-Energy X-Ray Absorptiometry Technical issues: the 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 109-22	3.5	37
33	Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. <i>Southern Medical Journal</i> , <b>2008</b> , 101, 735-9	0.6	23
32	Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 525-35	6.3	176
31	Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1391-7	4.1	111
30	A review of strontium ranelate and its effect on DXA scans. <i>Journal of Clinical Densitometry</i> , <b>2007</b> , 10, 113-9	3.5	33
29	Standards and guidelines for technologists performing central dual-energy X-ray absorptiometry. <i>Journal of Clinical Densitometry</i> , <b>2007</b> , 10, 189-95	3.5	12

28	Management of osteoporosis in men: an update and case example. <i>Cmaj</i> , <b>2007</b> , 176, 345-8	3.5	22
27	Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. <i>Bone</i> , <b>2007</b> , 40, 843-51	4.7	49
26	Strontium ranelate--data on vertebral and nonvertebral fracture efficacy and safety: mechanism of action. <i>Current Osteoporosis Reports</i> , <b>2006</b> , 4, 34-9	5.4	25
25	The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 36, 10-21	5.3	13
24	Bone strength: the whole is greater than the sum of its parts. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 36, 22-31	5.3	131
23	Effect of calcium tablets on interpretation of lumbar spine DXA scans. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 97-104	3.5	12
22	Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 22-30	3.5	93
21	Standards for performing DXA in individuals with secondary causes of osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 47-57	3.5	31
20	Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 4-14	3.5	116
19	Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international. <i>Clinical Drug Investigation</i> , <b>2006</b> , 26, 63-74	3.2	26
18	A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. <i>Osteoporosis International</i> , <b>2006</b> , 17, 159-66	5.3	29
17	Official positions of the International Society for Clinical Densitometry. <i>Osteoporosis International</i> , <b>2006</b> , 17, 1700-1	5.3	14
16	Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 1315-22	6.3	230
15	Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. <i>Endocrine Reviews</i> , <b>2005</b> , 26, 688-703	27.2	538
14	Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. <i>Journal of Clinical Densitometry</i> , <b>2004</b> , 7, 51-64	3.5	88
13	Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. <i>Maturitas</i> , <b>2004</b> , 48, 243-51	5	88
12	Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 15-28	3.5	124
11	Hadju-Cheney syndrome: response to therapy with bisphosphonates in two patients. <i>Journal of Bone and Mineral Research</i> , <b>2003</b> , 18, 131-3	6.3	23

10	Role of exercise and nutrition status on bone mineral density in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , <b>2003</b> , 2, 163-70	4.1	37
9	Intake of calcium and vitamin D in 3 Canadian long-term care facilities. <i>Journal of the American Dietetic Association</i> , <b>2002</b> , 102, 244-7		23
8	The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. <i>Calcified Tissue International</i> , <b>2002</b> , 71, 103-11	3.9	274
7	Diagnosis and management of vertebral fractures in elderly adults. <i>American Journal of Medicine</i> , <b>2002</b> , 113, 220-8	2.4	164
6	North American male reference population for speed of sound in bone at multiple skeletal sites. <i>Journal of Clinical Densitometry</i> , <b>2002</b> , 5, 63-71	3.5	13
5	Multisite bone ultrasound measurement on North American female reference population. <i>Journal of Clinical Densitometry</i> , <b>2001</b> , 4, 239-48	3.5	25
4	Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 2129-34	5.6	222
3	Alendronate for the treatment of osteoporosis in men. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 604-10	5.92	768
2	Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 382-7	59.2	608
1	The role of osteoanabolic agents in the management of patients with osteoporosis. <i>Postgraduate Medicine</i> , 1-11	3.7	1